23:28 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies identified a carboxamide-based 5-HT2C receptor positive allosteric modulator (PAM) that could help treat cocaine addiction. Chemical synthesis and in vitro activity testing of analogs of the 5-HT2C receptor PAM lincomycin yielded...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
18:47 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Phase III CAMELLIA-TIMI CVOT for Belviq ongoing

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said an independent DMC recommended continuation of the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial of Belviq lorcaserin (APD356) for chronic weight management. The DMC based its recommendation on...
22:06 , Jan 6, 2017 |  BC Week In Review  |  Company News

Arena, Eisai deal

Arena amended its licensing agreement with Eisai, granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Eisai will be responsible for all development and commercialization costs. Eisai already held rights...
01:33 , Jan 5, 2017 |  BC Extra  |  Company News

Arena sells off Belviq rights

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said it amended its licensing agreement with Eisai Co. Ltd. (Tokyo:4523), granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Arena said Eisai will be responsible...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Arena, Eisai sales and marketing update

Eisai launched Belviq XR lorcaserin extended release for chronic weight management. The wholesale acquisition cost (WAC) for a 20 mg tablet is $8.04. Belviq is approved in the U.S. as an adjunct to diet...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA approved an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The companies expect the drug to be available this fall. The approval triggered a $10 million...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA accepted an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The partners did not disclose the PDUFA date. The product is an extended-release formulation of twice-daily...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Arena pharmaceuticals news

Arena will reduce its U.S. workforce by about 80 (35%) by year end and make additional undisclosed cuts at its Arena Pharmaceuticals GmbH Swiss manufacturing facility. The cuts were brought on by lower than expected...